Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 4/2013

01-04-2013 | Original paper

Statin use and risk of bladder cancer: a meta-analysis

Authors: Xiao-long Zhang, Jiang Geng, Xiao-peng Zhang, Bo Peng, Jian-ping Che, Yang Yan, Guang-chun Wang, Sheng-qiang Xia, Yan Wu, Jun-hua Zheng

Published in: Cancer Causes & Control | Issue 4/2013

Login to get access

Abstract

Purpose

Emerging evidence suggests that statins may decrease the risk of cancers. However, available evidence on bladder cancer is conflicting. To quantify the association between statin use and risk of bladder cancer, we performed a detailed meta-analysis of published studies regarding this subject.

Methods

A literature search was carried out using MEDLINE, EMBASE, and OVID databases between January 1966 and October 2012. Before meta-analysis, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Fixed- and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95 % confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses, sensitivity analysis, and cumulative meta-analysis were also performed.

Results

A total of 13 (three RCTs, five cohort, and five case–control) studies contributed to the analysis. There was heterogeneity among the studies, but no publication bias. Pooled results indicated a nonsignificant increase in total bladder cancer risk among all statin users [RR = 1.07, 95 % CI (0.95, 1.21)]. Long-term statin use did not significantly affect the risk of total bladder cancer [RR = 1.21, 95 % CI (0.92, 1.59)]. In our subgroup analyses, the results were not substantially affected by study design, region, and confounder adjustment. Furthermore, sensitivity analysis confirmed the stability of the results.

Conclusions

The findings of this meta-analysis suggested that there was no association between statin use and risk of bladder cancer. More studies, especially RCTs, are needed to confirm this association.
Literature
1.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef
3.
4.
Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P et al (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52:1769–1781PubMedCrossRef
5.
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590PubMedCrossRef
6.
7.
Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:3602–3609PubMed
8.
Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508–519PubMedCrossRef
9.
Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P et al (2002) Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4:337–346PubMedCrossRef
10.
Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D et al (2002) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91:143–150PubMedCrossRef
11.
Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105:739–745PubMedCrossRef
12.
Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS et al (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50:83–93PubMedCrossRef
13.
Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y et al (2002) 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122:308–317PubMedCrossRef
14.
Kamat AM, Nelkin GM (2005) Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66:1209–1212PubMedCrossRef
15.
Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W et al (2001) Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 10:971–981PubMedCrossRef
16.
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388–2394PubMedCrossRef
17.
Kaye JA, Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90:635–637PubMedCrossRef
18.
Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O et al (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771–777PubMedCrossRef
19.
Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. 2005 Mar 16;3:6
20.
Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213–219PubMedCrossRef
21.
Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134–139PubMedCrossRef
22.
Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L et al (2010) Incidence of cancer and statin usage–record linkage study. Int J Cancer 126:279–284PubMedCrossRef
23.
Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763–1771PubMedCrossRef
24.
Kuo CC, Chiu HF, Lee IM, Kuo HW, Lee CT et al (2012) Statin use and the risk of bladder cancer: a population-based case-control study. Expert Opin Drug Saf 11:733–738PubMedCrossRef
25.
Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr et al (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27–36PubMedCrossRef
26.
Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409PubMedCrossRef
27.
Sato S, Ajiki W, Kobayashi T, Awata N (2006) Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16:201–206PubMedCrossRef
28.
Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74–80PubMedCrossRef
29.
Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120:833–843PubMedCrossRef
30.
Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C et al (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 7:e29849PubMedCrossRef
31.
Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 44:2122–2132PubMedCrossRef
32.
Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341PubMedCrossRef
33.
34.
35.
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRef
36.
Higgins JP, Thompson SG (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23:1663–1682PubMedCrossRef
37.
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef
38.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef
39.
40.
Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26–37PubMedCrossRef
Metadata
Title
Statin use and risk of bladder cancer: a meta-analysis
Authors
Xiao-long Zhang
Jiang Geng
Xiao-peng Zhang
Bo Peng
Jian-ping Che
Yang Yan
Guang-chun Wang
Sheng-qiang Xia
Yan Wu
Jun-hua Zheng
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 4/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0159-3

Other articles of this Issue 4/2013

Cancer Causes & Control 4/2013 Go to the issue

Brief report

Consumption of flaxseed, a rich source of lignans, is associated with reduced breast cancer risk

Original paper

Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository

Original paper

Childhood acute leukemia, maternal beverage intake during pregnancy, and metabolic polymorphisms

Review article

Red and processed meat intake and risk of colorectal adenomas: a systematic review and meta-analysis of epidemiological studies

Original paper

Bleomycin-induced mutagen sensitivity, passive smoking, and risk of breast cancer in Chinese women: a case–control study

Brief report

Intention to quit smoking and concerns about household environmental risks: findings from the Health in Common Study in low-income housing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits